|
1）Kanasaki K, Taduri G, Koya D. Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Front Endocrinol. 2013; 4: 7
|
|
|
|
|
2）He J, Xu Y, Koya D, et al. Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin Exp Nephrol. 2013; 17: 488-97
|
|
|
|
|
3）Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med. 2008; 14: 1236-46
|
|
|
|
|
|
4）Boye E, Olsen BR. Signaling mechanisms in infantile hemangioma. Curr Opin Hematol. 2009; 16: 202-8
|
|
|
|
|
|
5）Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008; 19: 2282-7
|
|
|
|
|
|
6）Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol. 2009; 175: 1380-8
|
|
|
|
|
|
7）LeBleu VS, Taduri G, O’Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013; 19: 1047-53
|
|
|
|
|
|
8）Xu-Dubois YC, Pettier J, Brocheriou I, et al. Markers of endothelial-to-mesenchymal transition: Evidence for antibody-endothelium interaction during antibody-mediated rejection in kidney recipients. J Am Soc Nephrol. 2015 May 20 [Epub ahead of print]
|
|
|
|
|
|
9）Zeisberg EM, Potenta S, Xie L, et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007; 67: 10123-8
|
|
|
|
|
|
10）Cooley BC, Nerado J, Mellad J, et al. TGF-beta signaling mediates endothelial-to-mesenchymal transition (EndMT) during vein graft remodeling. Sci Transl Med. 2014; 6: 227ra34
|
|
|
|
|
|
11）Chen PY, Qin L, Bames C, et al. FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep. 2012; 2: 1684-96
|
|
|
|
|
|
12）Xavier S, Vasco R, Matsumoto K, et al. Curtailing endothelial TGF-beta signaling Is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD. J Am Soc Nephrol. 2015; 26: 817-29
|
|
|
|
|
|
13）Kanasaki K, Nagai T, Nitta K, et al. N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes. Front Pharmacol. 2014; 5: 70
|
|
|
|
|
|
14）Kanasaki K, Koya D, Sugimoto T, et al. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol. 2003; 14: 863-72
|
|
|
|
|
|
15）Kanasaki K, Haneda M, Sugimoto T, et al. N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators. Biochem Biophys Res Commun. 2006; 342: 758-65
|
|
|
|
|
|
16）Omata M, Taniguchi H, Koya D, et al. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. J Am Soc Nephrol. 2006; 17: 674-85
|
|
|
|
|
|
17）Shibuya K, Kanasaki K, Isono M, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes. 2005; 54: 838-45
|
|
|
|
|
|
18）Nagai T, Kanasaki M, Srivastava SP, et al. N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition. Biomed Res Int. 2014; 2014: 696475
|
|
|
|
|
|
19）Nagai T, Nitta K, Kanasaki M, et al. The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis. Clin Exp Nephrol. 2015; 19: 65-74
|
|
|
|
|
|
20）Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014; 63: 2120-31
|
|
|
|
|
|
21）Shi S, Srivastava SP, Kanasaki M, et al. Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. Kidney Int. 2015; 88: 479-89
|
|
|
|
|